Skip to main content

Advertisement

SpringerLink
Log in

The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There is no information about XCL1 in patients with acute lymphoblastic leukemia (ALL). The objective of this study was to correlate the serum levels of XCL1 and survival in ALL patients. Only ALL patients older than 12 months were considered to participate. Serum XCL1 was measured at diagnosis, end of remission induction, and end of consolidation. Thirty-three ALL patients with median age of 21 years (1–78) were included. Higher XCL1 level (above 50 pg/mL) at ALL diagnosis correlated with higher survival (p = 0.038), whereas XCL1 level at end of induction and consolidation had no significant correlation. Concerning the behavior of serum XCL1 during treatment, higher survival at 5 years was observed in the group with progressively decreased levels of XCL1 (70%) than those with progressively increasing (29%) or no detectable XCL1 (14%). In conclusion, higher serum XCL1 levels at diagnosis and their progressive decline throughout chemotherapy could be correlated with higher survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gökbuget N, Stanze D, Beck J et al (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120:2032–2041

    Article  PubMed  Google Scholar 

  2. Rowe J (2010) Prognostic factors in adult acute lymphoblastic leukaemia. Brit J Haematol 150:389–405

    Google Scholar 

  3. Mazuri B, Mertas A, Sónta-Jakimczy K et al (2004) Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol Oncol 22:27–34

    Article  Google Scholar 

  4. Bruserud O, Ulvestad E (2003) Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells. Cancer Immunol Immunother 52:215–225

    CAS  PubMed  Google Scholar 

  5. Lei Y, Takahama Y (2012) XCL1 and XCR1 in the immune system. Microbes Infect 14:262–267

    Article  CAS  PubMed  Google Scholar 

  6. Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217–242

    Article  CAS  PubMed  Google Scholar 

  7. Rollins B (1997) Chemokines. Blood 90:909–928

    CAS  PubMed  Google Scholar 

  8. Ordway D, Higgins D, Sanchez-Campillo J et al (2007) XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-γ by CD4 T cells and participates in granuloma stability. J Leukoc Biol 82:1221–1229

    Article  CAS  PubMed  Google Scholar 

  9. Dong C, Chua A, Ganguly B et al (2005) Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity. J Immunol Methods 302:136–144

    Article  CAS  PubMed  Google Scholar 

  10. Visentini M, Carbonari M, Ghia E, De Propriis S et al (2006) A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. Leuk Lymphoma 47:1421–1423

    Article  PubMed  Google Scholar 

  11. Stievano L, Tosello V, Marcato N et al (2003) CD8þ alpha betaþ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol 171:4528–4538

    Article  CAS  PubMed  Google Scholar 

  12. Volkman B, Liu T, Peterson F (2009) Lymphotactin structural dynamics. Methods Enzymol 461:51–70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Huang H, Li F, Cairns F et al (2001) Neutrophilis and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem Biophys Res Commun 281:378–382

    Article  CAS  PubMed  Google Scholar 

  14. Rosas-Taraco A, Higgins D, Sánchez-Campillo J et al (2009) Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 41:136–145

    Article  CAS  PubMed  Google Scholar 

  15. Endres M, Andreas K, Kalwitz G et al (2010) Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells. Osteoarthr Cartil 18:1458–1466

    Article  CAS  PubMed  Google Scholar 

  16. Emtage P, Wan Y, Hitt M et al (1999) Adenoviral vectors expressing lymphotactin and interleukin-12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697–709

    Article  CAS  PubMed  Google Scholar 

  17. Cairns CM, Gordon JR, Li F et al (2001) Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J Immunol 167:57–65

    Article  CAS  PubMed  Google Scholar 

  18. Kelner GS, Kennedy J, Bacon KB et al (1994) Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395–1399

    Article  CAS  PubMed  Google Scholar 

  19. Cerdan C, Devilard E, Xerri L et al (2001) The C-class chemokine lymphotactin costimulates the apoptosis of human CD4(+) T cells. Blood 97:2205–2212

    Article  CAS  PubMed  Google Scholar 

  20. Hedrick JA, Saylor V, Figueroa D et al (1997) Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158:1533–1540

    CAS  PubMed  Google Scholar 

  21. Reikvam H, Fredly H, Kittang OA et al (2013) The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins 5:336–362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kornblau SM, McCue D, Singh N et al (2010) Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 116:4251–4261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bradley LM, Asensio VC, Schioetz LK, Harbertson J et al (1999) Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 162(5):2511–2520

    CAS  PubMed  Google Scholar 

  24. Klein M, Paul R, Angele B et al (2006) Protein expression pattern in experimental pneumococcal meningitis. Microbes Infect 8:974–983

    Article  CAS  PubMed  Google Scholar 

  25. Dorner BG, Smith HR, French AR et al (2004) Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J Immunol 172:3119–3131

    Article  CAS  PubMed  Google Scholar 

  26. Cerdan C, Serfling E, Olive D (2000) The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood 96:420–428

    CAS  PubMed  Google Scholar 

  27. Van Dongen J, Van der Velden V, Brüggemann M et al (2015) Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125:3996–4009

    Article  PubMed  PubMed Central  Google Scholar 

  28. Pérez-Figueroa E, Sánchez-Cuaxospa M, Martínez-Soto KA et al (2016) Strong inflammatory response and Th1-polarization profile in children with acute lymphoblastic leukemia without apparent infection. Oncol Rep 35:2699–2706

    Article  PubMed  Google Scholar 

  29. Gómez AM, Martínez C, González M et al (2015) Chemokines and relapses in childhood acute lymphoblastic leukemia: a role in migration and in resistance to antileukemic drugs. Blood Cell Mol Dis 55:220–227

    Article  Google Scholar 

Download references

Funding

The present investigation was sponsored with own resources of the Service of Hematology.

Author information

Authors and Affiliations

  1. Servicio de Hematología del Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo León, Madero y Gonzalitos sn Colonia Mitras Centro, C.P, 64460, Monterrey, Nuevo León, Mexico

    Cesar Homero Gutiérrez-Aguirre, Juan Antonio Flores-Jiménez, Julio Alatorre-Ricardo, Olga Graciela Cantú-Rodríguez, Rosario Salazar-Riojas, José Carlos Jaime-Pérez, Mónica Sánchez-Cárdenas, Leslie López-Silva & David Gómez-Almaguer

  2. Servicio de Inmunología de la Facultad de Medicina, Universidad Autónoma de Nuevo León, Gonzalitos #235 Norte. Mitras Centro. C.P, 64460, Monterrey, Nuevo León, Mexico

    Adrián Rosas-Taraco, Azalia M. Martínez-Castilla & Mario Cesar Salinas-Carmona

Authors
  1. Cesar Homero Gutiérrez-Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Antonio Flores-Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julio Alatorre-Ricardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olga Graciela Cantú-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adrián Rosas-Taraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rosario Salazar-Riojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. José Carlos Jaime-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mónica Sánchez-Cárdenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leslie López-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Azalia M. Martínez-Castilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mario Cesar Salinas-Carmona
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. David Gómez-Almaguer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cesar Homero Gutiérrez-Aguirre.

Ethics declarations

All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gutiérrez-Aguirre, C.H., Flores-Jiménez, J.A., Alatorre-Ricardo, J. et al. The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study. Ann Hematol 96, 2015–2024 (2017). https://doi.org/10.1007/s00277-017-3142-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3142-3

Keywords

Search

Navigation